Wellgistics Health Inc (WGRX)
NASDAQHealth CareMedical - DistributionSnapshot 2026-11-05
$3.59+15.06%
Close 2026-07-28 · 1-day change
NASDAQHealth CareMedical - DistributionSnapshot 2026-11-05
QuarterlyIQ Insights · WGRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.
Stated in 1 of 1 supplied quarters. Management reported: “Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.” “DataMeds aims to deliver a vertically aligned healthcare ecosystem to patients that expands EinsteinRx ™ ’s technological capabilities into medical, laboratory and wearables fields through a proprietary blockchain, leveraging unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases.” Revenue was $1.780 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.”
The planned share restructuring and new CUSIP support the Company’s next phase of growth.
Stated in 1 of 1 supplied quarters. Management reported: “The planned share restructuring and new CUSIP support the Company’s next phase of growth.” “Holders of DataMEDS common stock as of the new record date of August 7,2026 will be entitled to receive fifty (50) Dream Bowl 2026 Meme Coins for each share of DataMEDS common stock that they hold.” Operating income was $-7.345 million in 2026-Q2.
“The planned share restructuring and new CUSIP support the Company’s next phase of growth.”
Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.
Stated in 1 of 1 supplied quarters. Management reported: “Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.” “DataMeds aims to deliver a vertically aligned healthcare ecosystem to patients that expands EinsteinRx ™ ’s technological capabilities into medical, laboratory and wearables fields through a proprietary blockchain, leveraging unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases.” Net income was $-18.363 million in 2026-Q2.
“Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale.”
Meet or exceed the guided revenue target of $1.775 million for the second quarter of 2026.
Finalize acquisitions and partnerships including Datavault AI, Tollo Health, and Kare Pharmtech to enhance platform and patient engagement.
Over the trailing year it converted 0.08x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
63 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.